000309658 001__ 309658
000309658 005__ 20260205153003.0
000309658 0247_ $$2doi$$a10.1080/14737140.2026.2623059
000309658 0247_ $$2pmid$$apmid:41640088
000309658 0247_ $$2ISSN$$a1473-7140
000309658 0247_ $$2ISSN$$a1744-8328
000309658 037__ $$aDKFZ-2026-00290
000309658 041__ $$aEnglish
000309658 082__ $$a610
000309658 1001_ $$aHeymach, John V$$b0
000309658 245__ $$aThe role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.
000309658 260__ $$aAbingdon, Oxon$$bTaylor & Francis$$c2026
000309658 3367_ $$2DRIVER$$aarticle
000309658 3367_ $$2DataCite$$aOutput Types/Journal article
000309658 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770301793_2393090$$xReview Article
000309658 3367_ $$2BibTeX$$aARTICLE
000309658 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000309658 3367_ $$00$$2EndNote$$aJournal Article
000309658 500__ $$a#NCTZFB9# / epub
000309658 520__ $$aHER2 is mutated in 2-4% of non-small cell lung cancers (NSCLC) and is associated with poor prognosis. Tyrosine kinase inhibitors (TKIs) targeting HER2 have historically been hampered by insufficient efficacy against exon 20 insertion mutations and lack of specificity, resulting in off-target adverse events. Zongertinib is an oral, irreversible HER2-selective TKI that spares wild-type EGFR, thereby minimizing associated toxicities. Zongertinib was recently approved in the United States (accelerated), China (conditional), and Japan for patients with previously treated advanced HER2-mutant NSCLC.This article outlines the discovery and clinical development of zongertinib that led to these approvals. We discuss the first-in-human Beamion LUNG-1 trial (NCT04886804), in which zongertinib demonstrated encouraging and durable activity, with a manageable safety profile, in patients with HER2-mutant advanced NSCLC. Finally, we summarize ongoing clinical trials of zongertinib, including its assessment as first-line treatment for advanced HER2-mutant NSCLC.Zongertinib is the first oral TKI approved for HER2-mutant NSCLC and will provide patients with a convenient, tolerable and effective treatment option in an area of significant unmet need. Next steps include its potential transition to a first-line setting, identification of additional indications, and development of novel combination regimens.
000309658 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000309658 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000309658 650_7 $$2Other$$aZongertinib
000309658 650_7 $$2Other$$ahuman epidermal growth factor receptor 2
000309658 650_7 $$2Other$$anon-small cell lung cancer
000309658 650_7 $$2Other$$atargeted therapy
000309658 650_7 $$2Other$$atyrosine kinase inhibitor
000309658 7001_ $$aPopat, Sanjay$$b1
000309658 7001_ $$aSmit, Egbert F$$b2
000309658 7001_ $$0P:(DE-He78)a22d618e20924210eb7b3af630a45441$$aChristopoulos, Petros$$b3$$udkfz
000309658 7001_ $$aPlanchard, David$$b4
000309658 7001_ $$aYoshida, Tatsuya$$b5
000309658 7001_ $$aZugazagoitia, Jon$$b6
000309658 7001_ $$aYu, Yan$$b7
000309658 7001_ $$aWilding, Birgit$$b8
000309658 773__ $$0PERI:(DE-600)2090850-7$$a10.1080/14737140.2026.2623059$$gp. 14737140.2026.2623059$$pnn$$tExpert review of anticancer therapy$$vnn$$x1473-7140$$y2026
000309658 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a22d618e20924210eb7b3af630a45441$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000309658 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000309658 9141_ $$y2026
000309658 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEXPERT REV ANTICANC : 2022$$d2025-11-11
000309658 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-11
000309658 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-11
000309658 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-11
000309658 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-11
000309658 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-11
000309658 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-11
000309658 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-11
000309658 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-11-11
000309658 9201_ $$0I:(DE-He78)HD02-20160331$$kHD02$$lKoordinierungsstelle NCT Heidelberg$$x0
000309658 980__ $$ajournal
000309658 980__ $$aVDB
000309658 980__ $$aI:(DE-He78)HD02-20160331
000309658 980__ $$aUNRESTRICTED